Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2007

View Archived Issues

Variation Biotechnologies raises Series A financing

Preclinical characterization of sergliflozin, a novel selective SGLT2 inhibitor

Poniard and Scripps Research Institute to discover FAK inhibitors

Icagen updates sodium channel programs

Scynexis earns preclinical milestone payment from Merck collaboration

AstraZeneca and Bristol-Myers Squibb collaborate on type 2 diabetes compounds

MultiCell's anticancer combination therapy prevents disease recurrence

Biomedical Research Models licenses Neuralstem compounds in diabetes

Valeant and Metabasis close pradefovir licensing deal with Schering-Plough

CytRx establishes new RNAi subsidiary, RXi Pharmaceuticals

Droxidopa reduces fall in orthostatic systolic blood pressure

Astellas terminates agreement on carperitide for acute heart failure

Progress in phase I study of anticancer compound ECO-4601

Valeant licenses Canadian rights to Xyrem in cataplexy

BioInvent and Genentech collaborate on cardiovascular candidate BI-204

Stimuvax begins phase III study

FDA outlines issues regarding planned phase I study of ReN-001 stem cell therapy

Metastatic pancreatic cancer patients show clinical responses to talabostat therapy

Sativex shows utility in peripheral neuropathic pain

Promising preclinical results with raloxifene-derived selective estrogen receptor modulator

Mycamine launched in 100 mg vial format

Somatuline Autogel NDA accepted for filing

Novel TAFIa inhibitor profiled at Berlex

Recent sanofi-aventis patents report novel therapeutic agents for arrhythmia

Novel treatment options for HIV infection reported in recent patent literature

Recent Gruenenthal patent discloses new analgesic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...